Stanford University investigators recently concluded in a study that 1 in 5 COVID-19 hospitalized patients develop new antibodies that attack their own tissue within a week of admission. Called autoantibodies, that is, antibodies directed at their own tissue or at substances their immune cells secrete into the blood, COVID-19 patients are far more likely to encounter this dynamic than those individuals without COVID-19. Autoantibodies potentially indicate the potential for autoimmune disease. The study results indicate that those that wind up hospitalized with COVID-19 “…may not be out of the woods,” suggests Stanford Medicine’s PJ Utz, lead researcher and professor of immunology and rheumatology.
Published on September 14 in Nature Communications, the study team probed for autoantibodies in blood samples drawn during March and April of 2020 from 147 COVID-19 patients at the three university-affiliated hospitals in addition to a group of additional patients admitted to Kaiser Permanente. For the control group, the scientists included blood samples from additional donors.
As reported in Stanford Medicine News, the research team both identified as well as measured levels ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).